CDK7-IN-26

• Description :

  CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC50: 7.4 nM) . CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC50 of 0.15 μM[1].

• UNSPSC :

  12352005

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cdk7-in-26.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=P(C)(C1=C(C=CC2=C1NC=C2C3=NC(N[C@H]4C[C@H](F)CNC4)=NC5=C3SC=C5)C#N)C

• Molecular Formula :

  C22H22FN6OPS

• Molecular Weight :

  468.49

• References & Citations :

  [1]Zhang H et al. Discovery and optimization of thieno [3, 2-d] pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7[J]. European Journal of Medicinal Chemistry, 2023: 115955.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [3024545-79-4]